A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the succ ...

Investors with a lot of money to spend have taken a bullish stance on Exact Sciences EXAS. And retail traders should know. We noticed this today when the positions showed up on publicly available ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Stocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK start-up Base Genomics. Exact Sciences said it has agreed to buy Thrive for a cash and ...

Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced that a blood-based test it’s developing showed promise in accurately detecting the disease.

Analysts also raised price targets for Applovin and Arm Holdings. Wall Street Analysts Believe Exact Sciences Could Rally 34.33%: Here's is How to Trade Exact Sciences (NASDAQ: EXAS) closed the ...

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called ...

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly challenge his rival to a bet. Exact’s test could compete with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...